Scythian’s Chief Medical Officer, The Famed Dr. Barnes, Receives National Praise for His Advocacy, Education and Tireless Leadership from Government, Media and Medical Organizations to Assist in Making This Major Event Happen

TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. Specialist doctors in England, Wales and Scotland will be able to prescribe cannabis-derived medicines in less than a month.

The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy. Over the summer an urgent review of cannabis-based medicinal products was called following an outcry over two young epilepsy sufferers, Alfie Dingley and Billy Caldwell, being denied access to cannabis oil.

“Congratulations to the UK Government and Home Secretary Sajid Javid, and a special congratulations to our own Chief Medical Officer, Michael Barnes, whose years of work, collaborative efforts with members of government and insatiable dedication to legalizing medicinal cannabis use helped make this decision occur,” said CEO Brady Cobb. “Scythian is proud to have you as a senior leader of our team and strongly supports your ongoing initiatives.”

Professor Michael Barnes, a leading world authority in neurological rehabilitation and an influential leader in the medical cannabis sector, has been a powerful advocate for the medical use of cannabis in the United Kingdom. Through strategic relationships and key organizations such as endourpain.org, the United Patients Alliance and Clear, as well as his participation in the drug policy innovation hub Volteface, Professor Barns has helped facilitate the accomplishment of key milestones along the UK’s path to legalizing cannabis-derived medicines. One such milestone was reached this past July when Alfie Dingley became the first person in the UK to receive a long-term licence to be treated with medicinal cannabis.

Professor Barnes has lectured extensively on medical cannabis use across the globe, in addition to recording several live TV, radio, print and social media interviews on the topic. He has played an instrumental part in Sajid Javid’s groundbreaking decision to loosen regulations on prescribing medical cannabis in the UK.

“This is a historic day,” said Professor Michael Barnes. “Many people have campaigned for many years to get to this point. We still have a way to go, particularly for doctors’ education, but nevertheless beginning in November many tens of thousands of people with a whole range of medical conditions can at last access a medicine that will surely benefit their health.”

About Scythian Biosciences Corp.

Scythian is an international cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States medical cannabis industry.

CONTACT INFORMATION

Scythian Biosciences Corp.

Brady Cobb, CEO

Phone: (212) 729-9208

Email: info@scythianbio.com

For media inquiries, please contact:

David Schull or Nic Johnson

Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com

nic.johnson@russopartnersllc.com

Cautionary Statements

This press release contains certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation, statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Such forward-looking information includes information relating to CannCure’s acquisition of 3 Boys Farms and the Company’s proposed acquisition of CannCure.

Readers are cautioned to not place undue reliance on forward-looking information. Forward-looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Such risks and uncertainties include, among other things, the risk that a regulatory approval that may be required for any of the proposed acquisitions is not obtained or is obtained subject to conditions that are not anticipated, that a condition to the completion of the acquisition of CannCure may not be satisfied including the completion of satisfactory due diligence of CannCure and 3 Boys Farms by the Company or that the Company fails to successfully integrate CannCure into its current business.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those contained in the forward-looking information, there can be other factors that cause results or events to not be as anticipated, estimated or intended, including, but not limited to: the Company’s ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry; and regulatory or political change. Additional risk factors can also be found in the Company’s annual information form filed on SEDAR and available at www.sedar.com.

The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.